Pharvaris N.V. $PHVS Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP raised its stake in shares of Pharvaris N.V. (NASDAQ:PHVS) by 3.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 645,533 shares of the company’s stock after acquiring an additional 22,131 shares during the period. Rock Springs Capital Management LP owned approximately 0.99% of Pharvaris worth $18,236,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the 4th quarter valued at $35,000. Barclays PLC acquired a new stake in shares of Pharvaris in the 4th quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris in the 4th quarter worth $86,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Pharvaris during the fourth quarter worth about $110,000.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Royal Bank Of Canada lowered their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wedbush boosted their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. UBS Group set a $74.00 target price on Pharvaris in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $50.08.

Pharvaris Stock Performance

Pharvaris stock opened at $33.97 on Tuesday. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -10.68 and a beta of -2.34. Pharvaris N.V. has a fifty-two week low of $19.12 and a fifty-two week high of $36.60. The stock’s fifty day moving average is $32.56 and its two-hundred day moving average is $29.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts forecast that Pharvaris N.V. will post -2.97 EPS for the current fiscal year.

Insider Activity

In other Pharvaris news, Director Elisabeth Bjork sold 10,000 shares of Pharvaris stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total transaction of $293,200.00. Following the completion of the transaction, the director owned 15,167 shares in the company, valued at approximately $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Anne Lesage sold 30,703 shares of Pharvaris stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the transaction, the insider owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. The trade was a 24.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 274,555 shares of company stock worth $8,880,601 in the last three months.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.